WUXI BIO previously announced the sale of assets related to the Irish vaccine facility to Merck (MSD International) for a total price of approximately 0.5 billion USD. Citi released a Research Report stating that while WUXI BIO's move to divest specified overseas facilities aligns with market expectations, some may view the asset sale as a defensive action against potential geopolitical risks. The bank believes that the transaction concerning the Irish vaccine facility will not have a negative financial impact on the company and will improve its overall profitability. Citi set a Target Price of 30 HKD on WUXI BIO and gave a 'Buy' rating.
花旗：药明生物售爱尔兰疫苗设施对财务无负面影响并将改善整体盈利能力
Citi: The sale of WUXI BIO's Irish vaccine facility will not negatively impact finances and will improve overall profitability.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha